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Stem cells undergo symmetric and asymmetric divisions to generate differentiated cells
and more stem cells. The balance between self-renewal and differentiation of stem cells
is controlled by transcription factors, epigenetic regulatory networks, and microRNAs
(miRNAs). Herein the miRNA involvement in the regulation of stem cell self-renewal and
differentiation is summarized. miRNA contribution to malignancy through regulating can-
cer stem cells is described. In addition, the reciprocal associations between miRNAs and
epigenetic modiﬁcations in control of stem cell fate are discussed.
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INTRODUCTION
Stem cells are a small population of cells with the dual capaci-
ties for both self-renewal thereby producing more stem cells and
differentiation thereby generating specialized cell types (Draper
et al., 2004; Velasco-Velazquez et al., 2012). Through symmetric
division, one stem cell divides into two new stem cells. Through
asymmetric division, one stem cell divides into another stem
cell and one differentiating cell. Stem cells have been identiﬁed
from embryos and various adult tissues, as well as bone mar-
row and blood. Embryonic stem (ES) cells are pluripotent and
give rise to diverse cell types and tissues. Autologous adult stem
cell transplantation is considered as one of the most promising
strategies for tissue regeneration and medical therapy (Mullenix
et al., 2012).
The concept of stem cells has been extended to the cancer
ﬁeld by the discovery of stem-like cells within tumors, referred
to as cancer stem cells (CSCs). In contrast with ES and adult
stem cells, CSCs are characterized by not only self-renewal and
differentiation capacities, but also the ability to form tumors
when transplanted into an animal host (Rosen and Jordan, 2009).
CSCs have been isolated from different solid tumors including the
breast, lung, brain, and colon (Al-Hajj et al., 2003; Singh et al.,
2003; Rivera et al., 2011). CSCs are believed to be responsible for
chemo- and/or radiation-therapy resistance of cancer. Moreover,
CSCs may contribute to therapy relapse and tumor cell metastasis
(Velasco-Velazquez et al., 2012; Figure 1).
Multiple signaling pathways are involved in the early cell fate
decisions of ES cells, adult stem cells, and CSCs. Hormone
signal transduction pathways, transcription factors, epigenetic
modiﬁcations, and microRNAs (miRNAs) play important roles
in regulating self-renewal and differentiation of stem cells. The
epigenetic modiﬁcations include histone methylation, acetylation,
phosphorylation, and DNA methylation.
miRNAs are a class of multi-functional small RNA that are
single-stranded, ∼22 nt in length and do not encode proteins.
miRNAs regulate the stability or translational efﬁciency of targeted
messenger RNAs through complementary interactionwith the tar-
get genes. Each miRNA is predicted to target hundreds of genes. At
least one-third of human mRNAs could potentially be regulated
by miRNAs. miRNAs are involved in a broad range of biological
processes including embryonic development, self-renewal and dif-
ferentiation of stem cells, cell division and proliferation, initiation
and progression of cancer, and other diseases (Sotiropoulou et al.,
2009; Ye et al., 2009; Liu and Tang, 2011).
miRNAs are involved in stem cell self-renewal and differ-
entiation by targeting components that decide stem cell fate.
Following transport to the cytoplasm by Exportin-5, pre-miRNAs
are processed to mature miRNAs by Dicer and its partner TBRP.
Dicer-deﬁcient mouse ES cells are defective in the capacity to
self-renew or differentiate indicating the importance of mature
miRNAs inES cell self-renewal anddifferentiation (Kanellopoulou
et al., 2005). The transcription factors OCT4, SOX2, NANOG,
and KLF4 are important for the maintenance of “stemness.”These
“stemness” factors are able to reprogram somatic cells to a pluripo-
tent embryonic state (Takahashi and Yamanaka, 2006; Jaenisch
andYoung, 2008). miRNAs regulate the expression of these “stem-
ness” factors. miR-145 directly represses OCT4, SOX2, and KLF4,
inhibiting stem cell self-renewal and inducing differentiation (Xu
et al., 2009). In a regulatory feedback loop, OCT4 in turn represses
miR-145 expression (Xu et al., 2009). miR-134, miR-296, and
www.frontiersin.org September 2012 | Volume 3 | Article 191 | 1
“fgene-03-00191” — 2012/9/24 — 10:22 — page 2 — #2
Yu et al. miRNAs regulate stem cells
FIGURE 1 | Cancer stem cells play key roles during tumorigenesis,
relapse, and metastasis of cancer.
miR-470 target the coding region sequences of Nanog, Oct4, and
Sox2 genes in mouse ES cells (Tay et al., 2008). Bmi-1, a mem-
ber of the Polycomb family, regulates self-renewal of stem cells
by an epigenetic mechanism. Bmi-1 is activated in breast can-
cer stem cell (BCSC) and neural stem cell populations (Liu et al.,
2006; Godlewski et al., 2008). miR-128 targets Bmi-1, suppressing
CSC self-renewal and inhibiting tumorigenesis. In glioblastoma
cells, Bmi-1 upregulation is associated with the downregulation of
miR-128 (Godlewski et al., 2008). In addition to miR-128, miR-
200, miR-203, and miR-183 target Bmi-1 thereby regulating stem
cells (Shimono et al., 2009).
STEMNESS miRNAs
Several miRNAs promote stem cell self-renewal. Expression of the
miR-302-367 cluster is increased in stem cells, decreases after cell
differentiation, and is undetectable in somatic cells. The miR-
302-367 cluster, which includes miR-302a/b/c/d and miR-367,
was originally cloned from human and mouse ES cells. The miR-
302-367 cluster re-expression reprogrammed mouse and human
somatic cells to a pluripotent stem cell state (Anokye-Danso et al.,
2011), and reprogrammed cancer cells into an ES-like pluripotent
stem cell with high expression of Oct3/4, SSEA-3, SSEA-4, Sox2,
and Nanog (Lin et al., 2008). These ﬁndings suggest the miR-302-
367 cluster plays a role in a cellular plasticity event by promoting
“stemness” of both somatic and CSCs.
The promoter of the miR-302 cluster is regulated by Oct4
and Sox2 – two transcription factors required for stem cell
maintenance (Card et al., 2008). The miR-302-362 cluster, in turn,
regulates the expression of cyclin D1 and CDK4 – two ﬁne-tuning
regulators of G1/S cell cycle transition and progenitor cell function
(Card et al., 2008). As such, theOct4/Sox2-miR-302-cyclinD1net-
work may play an important role in maintaining the pluripotency
and self-renewal properties of stem cells.
DIFFERENTIATION miRNAs
miRNAs can induce cellular differentiation by inhibiting cell cycle
transition or epithelial to mesenchymal transition (EMT), inhibit-
ing “stemness” factors either genetic (Sox2, Oct, and Nanog) or
epigenetic (Bmi-1). Several miRNAs have very low level expres-
sion in stem cells which increases upon differentiation. Expression
of the let-7 miRNA family is reduced in cancer (Takamizawa
et al., 2004; Yu et al., 2007). let-7 expression is very low or unde-
tectable in BCSCs, and reduced let-7 expression is required for
the maintenance of “stemness.” let-7 has high expression in
differentiated cells. let-7 overexpression suppressed BCSC mam-
mosphere formation and tumor formation in mice (Yu et al.,
2007). After precession by Dicer and TBRP, mature miRNAs
associate with Argonaute (Ago) to regulate mRNA expression
through the RNA-induced silencing complex (RISC). Trim71,
a target gene of let-7, associates with Argonaute 2 and miR-
NAs to repress Cdkn1a (p21CIP1) expression, thereby inducing
the G1/S cell cycle phase transition to promote self-renewal of
ES cells (Chang et al., 2012). let-7 delivery has been used in
cancer treatment in an animal model (Esquela-Kerscher et al.,
2008). miR-200c also targets the Polycomb family member Bmi-
1. miR-200c inhibited mammary stem cell differentiation into
mammary ducts and inhibited human BCSC tumor formation
in vivo (Shimono et al., 2009). In breast cancer cells, miR-200
expression initiated mesenchymal to epithelial transition (MET)
by targeting ZEB1 and ZEB2 (Eger et al., 2005). In glioblastoma,
the aberrant cellular proliferation and self-renewal was associ-
ated with decreased expression of miR-128, which targets Bmi-1
(Godlewski et al., 2008). miR-34 inhibited tumor sphere growth
and tumor formation through targeting the notch signaling path-
way, which is one of the most important regulators of stem cells
(Ji et al., 2009).
miRNAs involved in stem cell differentiation often show
reduced abundance in cancer tissues, consistent with their role as
tumor suppressors. Overexpression of these miRNAs inhibits CSC
self-renewal, suggesting miRNA overexpression may be useful as a
therapeutic for cancer.
EPIGENETIC MODIFICATION AND miRNA EXPRESSION
Emerging evidence has identiﬁed feedback loops governing the
epigenetic regulation of stem cells through miRNAs (Krutovskikh
and Partensky, 2011; Liep et al., 2012). Histone modiﬁcation
and DNA methylation regulate expression of miRNAs. Similar
to protein-coding genes, miRNAs are originally transcribed from
genomic DNA, which may be affected by chromatin structure.
Epigenetic modiﬁcations can alter chromatin folding resulting
in the change of chromatin structure and thereby repressing or
stimulating miRNA expression (Figure 2). Epigenetic regulation
of miRNA expression has been reported in various diseases,
including cancer (Saito and Jones, 2006; Lujambio et al., 2007;
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FIGURE 2 | Regulatory networks between epigenetic modification and
miRNAs. HMT, histone methyltransferase; DMT, DNA methyltransferase;
Me, methylation.
Liep et al., 2012). Epigenetic silencing of tumor suppressor miR-
NAs through CpG island promoter hypermethylation is emerging
as a common hallmark of human tumors (Saito and Jones, 2006;
Lujambio et al., 2007, 2008). For example, hypermethylation-
related silencing of miR-148a, miR-34b/c, and miR-9 in human
cancer cells is associated with lymph node metastasis (Lujambio
et al., 2008). miRNA-124a undergoes transcriptional inactivation
by CpG island hypermethylation in human tumors (Lujambio
et al., 2007).
miRNA in turn regulate the expression of epigenetic modi-
ﬁers and transcription factors through direct target interaction
and/or indirect regulation of upstream pathways (Wiklund et al.,
2010, 2011). For example, miR-148 can negatively regulate
DNA methyltransferase expression, resulting in hypomethyla-
tion of DNA (Braconi et al., 2010). miR-449a targets histone
deacetylase-1, inhibiting the expression of histone deacetylase-1,
thereby inducing growth arrest of prostate cancer cells (Noonan
et al., 2009).
Through these regulatory interactions, miRNAs and epigenetic
modiﬁcation create a feedback and/or feedforward mechanism
through which gene expression is tightly controlled (Liep et al.,
2012). Aberrations in these epigenetic control systems governing
miRNA expression may contribute to the development of human
disease.
miRNA REGULATION OF CANCER STEM CELLS
Evidence for the function of CSCs began with human acute
myeloid leukemia (AML; Lapidot et al., 1994), in which AML-
initiating cells were identiﬁed from patients on the basis of the
cell surface marker CD34++CD38− expression. Upon transplan-
tation into severe combined immune-deﬁcient (SCID) mice, this
cell population homed to the bone marrow and showed a pat-
tern of dissemination and leukemic cell morphology similar to
the original patients. Subsequently, CSCs have been identiﬁed in
a variety of solid tumors, including breast, brain, colon, pancreas,
lung, prostate, liver, melanoma, glioblastoma, and head and neck
cancer. The CSCs have been deﬁned by expression of distinct tis-
sue type-speciﬁc cell surface marker including CD44, CD24, and
CD133 (Al-Hajj et al., 2003; Singh et al., 2003).
Cancer stem cells undergo asymmetric cell division to main-
tain both a stem cell and a differentiated cancer cell population.
As CSCs are often resistant to chemotherapy and/or radiation-
therapy,CSCs are thought likely to contribute to tumor recurrence.
miRNAs are involved in the regulationof CSC self-renewal anddif-
ferentiation (Bartel, 2004; Shimono et al., 2009). A CSC-speciﬁc
miRNA expression proﬁle has been reported (Shimono et al.,
2009) and altered expression of miRNAs has been identiﬁed in
cancer stem/ progenitor cells which vary by tumor type (Qian
et al., 2008; Shimono et al., 2009). A recent report deﬁned dis-
tinct miRNA expression patterns in various stem/progenitor cell
populations in prostate cancer, demonstrating the downregula-
tion of tumor suppressor miRNAs including miR-34 and let-7
in prostate CSCs (Liu et al., 2012), which revealed a coordina-
tion of miRNAs in regulating CSC self-renewal and cancer cell
proliferation.
CONCLUDING REMARKS
In view of the changes in miRNA abundance in a range of human
diseases including cancer, miRNAs are expected to be targeted for
therapy. Synthetic miRNA mimics and DNA expression vectors
containing miRNA precursor sequences have strong potential as
therapeutic tools. Although the therapeutic trial of miRNA mim-
ics or expression vectors in animal models has been reported to
suppress tumor growth (Esquela-Kerscher et al., 2008; Kota et al.,
2009), the ideal delivery system with the characteristics of high
transfection efﬁciency, low cellular toxicity, protection of miRNAs
from degradation, and tissue-speciﬁc delivery remains a challenge.
The side effects of miRNA therapy to date result from either
off-target tissue effects in other organs or altered gene expres-
sion from off-target gene effects as miRNA targets multiple genes.
In addition, the onco-miRNAs make them excellent targets for
cancer drug treatment. Chemically modiﬁed miRNA antisense
oligonucleotides have successfully inhibited target miRNA in vitro
(Zhu et al., 2007) and in vivo (Garchow et al., 2011). Using this
technique, a new anti-cancer approach targeting the oncogenic
miRNAs is being adapted for clinical application. Interestingly,
the discovery of circulatingmiRNA in body ﬂuids including serum
FIGURE 3 | Graphic of the reciprocal association between microRNAs
and epigenetic modifications in control of stem cell division.
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suggests miRNAs may have the potential to serve as diagnostic
or prognostic biomarkers for human disease (Gilad et al., 2008;
Kosaka et al., 2010).
In summary, stem cells are controlled by genetic and epigenetic
regulatory networks that maintain the balance between self-
renewal and differentiation. The epigenetic regulation includes
a variety of modiﬁcations that affect DNA methylation and his-
tone modiﬁcation. miRNAs regulate the stem cell characteristics
through regulating the expression of transcription factors. miRNA
genes are in turn subjected to epigenetic modiﬁcation, and miR-
NAs themselves can modify chromatin structures (Figure 3).
The cooperative association and reciprocal interactions between
genetic and epigenetic regulatory factors and miRNAs regulate
the self-renewal and differentiation of stem cells, and/or repro-
gramming of differentiated cells to induced pluripotent stem
cells.
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